Mendus

.Hero-module--bg-image--629a6:before { opacity: 1; background-image: url('/static/64ff3c5dc09358fb1f6e6ee5f4a8dcf4/e65ba/Mendus_woman-with-surfboard_darker-min-compress.jpg'); }

Changing the course of cancer treatment
We harness the power of the body's immune system to keep tumor cells in check without harming health or quality of life.

<picture><source type="image/webp" srcSet="/static/f6777646b01027295d9a7ee75dea7c96/dbb21/disarming-cancer-threat.webp 151w,/static/f6777646b01027295d9a7ee75dea7c96/8cdf4/disarming-cancer-threat.webp 302w,/static/f6777646b01027295d9a7ee75dea7c96/39272/disarming-cancer-threat.webp 603w" sizes="(min-width: 603px) 603px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 603px) 603px, 100vw" decoding="async" loading="lazy" src="/static/f6777646b01027295d9a7ee75dea7c96/d2caf/disarming-cancer-threat.jpg" srcSet="/static/f6777646b01027295d9a7ee75dea7c96/bedb7/disarming-cancer-threat.jpg 151w,/static/f6777646b01027295d9a7ee75dea7c96/8f82e/disarming-cancer-threat.jpg 302w,/static/f6777646b01027295d9a7ee75dea7c96/d2caf/disarming-cancer-threat.jpg 603w" alt="&lt;p&gt;Middle aged man running in a field of grass, surrounded by mountains.&lt;/p&gt;
"/></picture>
Gaining the 
upper handToday, tumor recurrence causes the vast majority of cancer-related deaths. We want to change this by designing new therapeutic options that tip the balance in favor of the immune system.
What we do

<picture><source type="image/webp" srcSet="/static/aafedabe406814250bbca33ccd38dca0/5b094/ways-to-make-dif.webp 225w,/static/aafedabe406814250bbca33ccd38dca0/ecbb3/ways-to-make-dif.webp 450w,/static/aafedabe406814250bbca33ccd38dca0/10d3d/ways-to-make-dif.webp 900w" sizes="(min-width: 900px) 900px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 900px) 900px, 100vw" decoding="async" loading="lazy" src="/static/aafedabe406814250bbca33ccd38dca0/a3b1e/ways-to-make-dif.jpg" srcSet="/static/aafedabe406814250bbca33ccd38dca0/51892/ways-to-make-dif.jpg 225w,/static/aafedabe406814250bbca33ccd38dca0/ea40c/ways-to-make-dif.jpg 450w,/static/aafedabe406814250bbca33ccd38dca0/a3b1e/ways-to-make-dif.jpg 900w" alt=""/></picture>
New ways to make a differenceWe dare to shine the light of science down new and unexplored paths to improve the course of cancer treatment.
About us

Latest newsAll news
6 February 2023Latest
Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group (“Negma”) has by notice to Mendus requested the...
Learn more
31 January 2023
Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group (“Negma”) has by notice to Mendus requested the...
Learn more
31 January 2023
DCP-001 becomes vididencel
Learn more
30 January 2023
Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group (“Negma”) has by notice to Mendus requested the...
Learn more
5 January 2023
Mendus AB: Mendus announces request of first tranche of convertible loan from Negma Group
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that the Company has requested the first tranche of a...
Learn more
14 December 2022
Replay of ASH 2022 Data Webcast
Learn more
12 December 2022
Mendus AB: Mendus presents positive survival data from the ADVANCE II trial evaluating DCP-001 as a maintenance therapy in AML at the American Society of Hematology (ASH) meeting
MENDUS TO HOST A WEBCAST TO DISCUSS THE ASH DATA ON TUESDAY, DECEMBER 13, 2022 AT 8.00AM ET/2.00PM CET    Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies...
Learn more

For investors
Invest in future cancer careMendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.
Investors
<picture><source type="image/webp" srcSet="/static/e3517795e1f9bcda1e6401e0dac3e35e/7bc26/124.webp 414w,/static/e3517795e1f9bcda1e6401e0dac3e35e/5e603/124.webp 828w,/static/e3517795e1f9bcda1e6401e0dac3e35e/af8c4/124.webp 1656w" sizes="(min-width: 1656px) 1656px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1656px) 1656px, 100vw" decoding="async" loading="lazy" src="/static/e3517795e1f9bcda1e6401e0dac3e35e/89e2a/124.jpg" srcSet="/static/e3517795e1f9bcda1e6401e0dac3e35e/1d336/124.jpg 414w,/static/e3517795e1f9bcda1e6401e0dac3e35e/8753d/124.jpg 828w,/static/e3517795e1f9bcda1e6401e0dac3e35e/89e2a/124.jpg 1656w" alt="&lt;p&gt;Close up of a middle aged woman dressed in a blazer, sitting down while looking at another person in the foreground.&lt;/p&gt;
"/></picture>
Latest presentation19 January 2023Corporate Presentation - Jan. 2023
30 November 2022Replay of Mendus' KOL Event
13 December 2022Replay of ASH 2022 Webcast
Financial calendar17 February 2023Publication of Year-end Report 2022
12 May 2023Annual General Meeting
12 May 2023Publication of Q1 Report
29 August 2023Publication of Q2 Report
9 November 2023Publication of Q3 Report
14 February 2024Publication of Year-end Report 2023

EventsAll events
22 February 2023
Upcoming
Redeye Theme: Regenerative Medicine / Cell TherapyMendus CEO Erik Manting will present and participate in an on-site Q&A session on February 22nd, 2023.
Learn more
January 2023Previous
12th Annual LifeSci Partners Corporate Access Event
Members of Mendus’ leadership team and Business Development team will be in San Francisco during the JPM Annual Healthcare Meeting 2023.
Learn more
December 2022Previous
Webcast – 64th American Society of Hematology Annual Meeting
Updated results from the Phase 2 ADVANCE II clinical trial were presented in an oral presentation on December 12. In addition, the company presented immunomonitoring data in a separate poster presentation on December 10. 

A replay of the webcast held on December 13 is available via the link below.
Learn more
November 2022Previous
Replay of KOL event on immunotherapy for maintenance treatment of AML patients in remission
Mendus hosted a key opinion leader (KOL) webinar highlighting the current state of maintenance treatment and immunotherapy in acute myeloid leukemia (AML) patients. The event featured two leading clinical experts, Assoc. Prof. Dr. Amer Zeidan, MBBS, MHS, from the Yale School of Medicine, and Prof. Dr. med. Uwe Platzbecker, from the Leipzig University Hospital.
Learn more

.FullWidthImage-module--bg-image-mobile--ba5fc.FullWidthImage-module--hide-in-mobile--9cd89.gbi--1792894973-uZK25Q8uDoiQBNKeYoSg6j:before { opacity: 1; background-image: url('/static/db5cac225ec6b40b3e48015942da980e/d3468/home-section-fullwidth.jpg'); }

A life-changing careerAt Mendus, we share a strong commitment to improve the lives of people with cancer. And we do it as a team who values honesty and togetherness. Join us and help change cancer treatment at its core.
Careers

Changing the course of cancer treatment

Gaining the upper hand

New ways to make a difference

Latest news

Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group

Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group

DCP-001 becomes vididencel

Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group

Mendus AB: Mendus announces request of first tranche of convertible loan from Negma Group

Replay of ASH 2022 Data Webcast

Mendus AB: Mendus presents positive survival data from the ADVANCE II trial evaluating DCP-001 as a maintenance therapy in AML at the American Society of Hematology (ASH) meeting

For investors

Invest in future cancer care

Latest presentation

Financial calendar

Events

Redeye Theme: Regenerative Medicine / Cell Therapy

12th Annual LifeSci Partners Corporate Access Event

Webcast – 64th American Society of Hematology Annual Meeting

Replay of KOL event on immunotherapy for maintenance treatment of AML patients in remission

A life-changing career

Keep up to date

Gaining the
upper hand